Stephens Consulting’s CG Oncology CGON Stock Holding History

Stephens Consulting’s Portfolio CGON Stock Details CGON Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2025 Q2	–	Sell	-15	Closed	-$368	–	1343
2025 Q1	$368	Buy	+15	New	+$422	﹤0.01%	1212

Other funds holding CGON

Decheng Capital Menlo Park, California $661M AUM 299.97% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return

TCM

TCG Crossover Management Palo Alto, California $3.5B AUM 1,165.83% 1-Year Est. Return

Braidwell Stamford, Connecticut $3B AUM 46.72% 1-Year Est. Return

KCM

Kynam Capital Management Princeton, New Jersey $1.62B AUM 138.67% 1-Year Est. Return

UBS Group Zurich, Switzerland $666B AUM 30.12% 1-Year Est. Return

FCMV

Foresite Capital Management VI Larkspur, California $460M AUM 261.77% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

Stephens Consulting's CGON Position: Q2 2025 in Review

Stephens Consulting sold out of CG Oncology (CGON) in Q2 2025, closing a stake of 15 shares — an estimated $368 sold.

Stephens Consulting first reported a position in CGON in Q1 2025 and held it in 1 quarter. The position peaked at $368 in Q1 2025. 162 funds tracked by Wall St. Rank hold CGON as of Q2 2025.

Stephens Consulting reported no remaining CG Oncology position as of Q2 2025 after selling out during the quarter.
Stephens Consulting sold 15 CG Oncology shares in Q2 2025, an estimated $368.
Stephens Consulting first reported a position in CG Oncology in Q1 2025 and held it in 1 quarter.
Stephens Consulting's CG Oncology position peaked at $368 in Q1 2025.
162 funds tracked by Wall St. Rank held CG Oncology as of Q2 2025.

Based on Stephens Consulting's 13F filing for Q2 2025, filed 25 Jul 2025.